Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments [0.03%]
阿伐曲泊帕片治疗对其他治疗手段耐药的成人原发免疫性血小板减少症患者的预算影响分析
Andrea Aiello,Elisa Elena Mariano,Mariangela Prada et al.
Andrea Aiello et al.
Introduction: Primary immune thrombocytopenia is a rare autoimmune disease characterised by a decreased platelet count resulting in an increased risk of bleeding events and even life-threatening haemorrhages. Thrombopoietin receptor agonist...
Transformative potential of artificial intelligence in global health policy [0.03%]
人工智能在全球卫生政策中的变革潜力
Ridwan Islam Sifat,Upali Bhattacharya
Ridwan Islam Sifat
Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement [0.03%]
中国创新药物的可及性与国家医保目录：定价与报销的现状、变化及其未来趋势
Bérengère Macabeo,Liam Wilson,Jianwei Xuan et al.
Bérengère Macabeo et al.
Background and objectives: Multiple reforms aimed at improving the Chinese population's health have been introduced in recent years, including several designed to improve access to innovative drugs. We sought to review cu...
The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy's multi-stakeholder pre-convention questionnaire [0.03%]
利益相关者参与在不断发展的欧盟HTA过程中的作用：通过欧洲准入学院的多利益相关者会前问卷调查获得的见解
Lauren Van Haesendonck,Jörg Ruof,Thomas Desmet et al.
Lauren Van Haesendonck et al.
Involvement of all relevant stakeholders will be of utmost importance for the success of the developing EU HTA harmonization process. A multi-step procedure was applied to develop a survey across stakeholders/collaborators within the EU HTA...
Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States [0.03%]
评估地拉斯特罗加莫克斯帕洛佩克（SRP-9001）基因疗法在美国杜氏肌营养不良症患者中的价值
Alexa C Klimchak,Lauren E Sedita,Louise R Rodino-Klapac et al.
Alexa C Klimchak et al.
Background: Delandistrogene moxeparvovec (SRP-9001) is an investigational gene therapy that may delay progression of Duchenne muscular dystrophy (DMD), a severe, rare neuromuscular disease caused by DMD gene mutations. Early cost-effectiven...
Quantitative revenue estimates and qualitative assessments of innovative fundraising sources for treating rare diseases in Colombia [0.03%]
哥伦比亚罕见病创新筹资渠道的定量收入估算与定性评估
Surrey M Walton,Wilson Mayorga,Angela Rodríguez Narváez et al.
Surrey M Walton et al.
Background: Like many developing countries, Colombia faces difficulties in financing health-care services as well as programs for health promotion and health education and there is evidence that its health-care system is underperforming. Ob...
Artificial intelligence and remote patient monitoring in US healthcare market: a literature review [0.03%]
美国医疗市场远程患者监护人工智能应用的文献综述
Ayushmaan Dubey,Anuj Tiwari
Ayushmaan Dubey
Background: Artificial intelligence (AI) enables remote patient monitoring (RPM) which reduces costs by triaging patients to optimize hospitalization and avoid complications. The FDA regulates AI in medical devices and ai...
Implementation of equity and access in Indian healthcare: current scenario and way forward [0.03%]
印度医疗卫生领域均等化与普惠性的现状及未来方向分析研究
Canna Ghia,Gautam Rambhad
Canna Ghia
Introduction: The Indian healthcare system is evolving towards better healthcare implementation and coverage. However, even today, the health-care system faces several challenges, a few of which are yet to be addressed. T...
Projecting direct medical costs and productivity benefits of improving access to advanced therapy for rheumatoid arthritis: a projection modelling study [0.03%]
改善类风湿关节炎先进治疗的可及性对其直接医疗费用和生产率效益的影响：预测模型研究
Chee Yoong Foo,Nurul Azwani Nadia Mansor,Shereen Suyin Ch&#x;ng et al.
Chee Yoong Foo et al.
Introduction: To ensure the sustainability of the AT access improvement, it is important that health system stakeholders have timely, analyzed information accessible for reference and decision-making support. In this stud...
Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy [0.03%]
意大利安卡林用于治疗地中海发热族系性疾病的预算影响分析
A Aiello,E E Mariano,M Prada et al.
A Aiello et al.
Introduction: Familial Mediterranean Fever (FMF) is a hereditary autoinflammatory disease that significantly reduces occupational productivity and quality-of-life in affected patients. Italy has an estimated FMF prevalenc...